Urologic Oncology Articles | Page 2

McDermott Shares Insight on Immunotherapy in RCC
David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.
FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC
The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.
Japan Approves Pembrolizumab for Urothelial Carcinoma
The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy
Reflecting Back, Looking Forward in Urology Practice
Because of vertical integration, this has allowed us to maintain economic stability in the face of diminishing reimbursement for professional services.
Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.
Role of PARP Inhibitors Developing in mCRPC
Alicia Morgan, MD, discusses the role of PARP inhibitors as a novel treatment strategy for patients with metastatic castration-resistant prostate cancer.
FDA Grants Frontline Avelumab/Axitinib Breakthrough Designation for RCC
The FDA has granted the PD-L1 inhibitor avelumab a breakthrough therapy designation for use in combination with the VEGF inhibitor axitinib in treatment-naïve patients with advanced renal cell carcinoma.
 
Future of Bladder Cancer Likely to Be Combination Immunotherapy
Arjun Balar, MD, discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.
FDA Grants Apalutamide Priority Review for Nonmetastatic CRPC
The FDA has granted a priority review to a new drug application for apalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
FDA Approves Frontline Cabozantinib for Advanced RCC
The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma.
Publication Bottom Border
Border Publication
x